Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

NCT02447666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Leukemia, Myelomonocytic, Juvenile

Interventions

DRUG: Azacitidine

Sponsor

Celgene